- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3217EUR$3,500USD£2,742GBP
- Report
- September 2024
- 82 Pages
Japan
From €3217EUR$3,500USD£2,742GBP
- Report
- July 2024
- 182 Pages
Global
From €4137EUR$4,500USD£3,526GBP
- Report
- May 2024
- 182 Pages
Global
From €4137EUR$4,500USD£3,526GBP
- Report
- November 2023
- 78 Pages
France
From €3217EUR$3,500USD£2,742GBP
- Report
- November 2023
- 78 Pages
Germany
From €3217EUR$3,500USD£2,742GBP
- Report
- December 2022
- 115 Pages
Global
From €4137EUR$4,500USD£3,526GBP
- Report
- August 2025
- 197 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- November 2023
- 120 Pages
Asia Pacific
From €3677EUR$4,000USD£3,134GBP
- Report
- December 2024
- 200 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- December 2024
- 200 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- October 2024
- 200 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- May 2024
- 200 Pages
Global
From €3815EUR$4,150USD£3,251GBP
- Report
- May 2024
- 200 Pages
Global
From €3815EUR$4,150USD£3,251GBP
- Report
- August 2023
- 145 Pages
Global
From €2896EUR$3,150USD£2,468GBP
- Report
- July 2023
- 145 Pages
Global
From €2896EUR$3,150USD£2,468GBP
- Report
- August 2025
- 195 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- August 2025
- 186 Pages
Global
From €3259EUR$3,545USD£2,777GBP
€3621EUR$3,939USD£3,086GBP
- Report
- July 2024
- 171 Pages
Global
From €4137EUR$4,500USD£3,526GBP
- Report
- September 2023
- 115 Pages
Global
From €4137EUR$4,500USD£3,526GBP

The CAS9 market is a subset of the genomics industry that focuses on the development and use of the CRISPR-Cas9 gene-editing technology. This technology is used to modify the genetic code of living organisms, allowing for the manipulation of genes and the potential to create new treatments for diseases. CAS9 is a powerful tool for researchers, allowing them to make precise changes to the genetic code of organisms.
The CAS9 market is growing rapidly, with many companies investing in the technology and its applications. Companies such as Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Caribou Biosciences are leading the way in developing and commercializing the technology. Other companies such as Horizon Discovery, Synthego, and Twist Bioscience are also investing in the CAS9 market, providing tools and services to researchers. Show Less Read more